Company Reports

Royalty Pharma increased its top-line portfolio receipts figure by 6% in the second quarter, partially skewed by a one-time distribution received last year. It lifted 2026 guidance by 2%. Shares traded flat on Aug. 5.

Royalty Pharma delivered 10% growth in portfolio receipts during the first quarter, leading management to lift guidance for their revenue proxy by about 100 basis points. Adjusted EBITDA increased 21% and the firm announced capital deployment of $528 million in the quarter.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Royalty Pharma totaled $874 million in portfolio receipts for the fourth quarter, increasing its revenue by 18% year over year. The firm announced four recent royalty transactions worth up to $4.7 billion and provided fiscal 2026 guidance that includes a receipt growth midpoint of 5.5%.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Royalty Pharma's third quarter delivered sustained revenue growth with portfolio receipts rising 11% year over year. Management increased guidance during the call, as 2025's midpoint for portfolio receipt growth is now expected to be 15%, up from 10.5%.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Royalty Pharma increased its portfolio receipts 20% year over year in the second quarter of 2025, announced a partnership with Revolution Medicines worth up to $2 billion, and completed an acquisition of its external manager with overwhelming shareholder support.

Narrow-moat Royalty Pharma delivered another strong quarter that was in line with our expectations. Portfolio receipts grew 17% year over year to $839 million, and the company raised their 2025 guidance for annual growth in portfolio receipts to a range of 6%-12%, up from the previous 4%-9% growth expectation. We maintain our $47 fair value estimate, and shares are trading in 5-star territory, presenting an attractive opportunity for long-term investors.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Narrow-moat Royalty Pharma’s fourth-quarter results largely tracked our expectations. Portfolio receipts for the quarter totaled $742 million, a 1% year-over-year increase. This growth was driven primarily by strong performance from key products including Evrysdi, the cystic fibrosis portfolio, Trelegy, Xtandi, and Tremfya. Royalty Pharma’s growth was tempered by a decline in milestone and other contractual receipts, notably a $50 million payment in the prior period related to the oral formulation of zavegepant. Despite this, the company’s core royalty receipt performance remained robust, bolstered by a diversified portfolio of leading biopharmaceutical products. We maintain our $47 fair value estimate.

Narrow-moat Royalty Pharma’s third-quarter results came in line with our expectations. We are maintaining our $47 fair value estimate. We are encouraged by the progress with the company’s high-quality portfolio, especially the approval of Bristol’s schizophrenia drug Cobenfy (formerly known as KarXT). We view Royalty Pharma’s shares as deeply undervalued and continue to think the market is underappreciating the long-term potential of its diversified portfolio.

Narrow-moat Royalty Pharma reported second-quarter results in line with our expectations. However, we are lowering our fair value estimate to $47 from $52 due to heightened risks from the company’s ongoing royalty rate dispute with narrow-moat Vertex Pharmaceuticals over the new vanza triple drug. Vertex has submitted the new drug application to the US and EU regulators for review, with an expected regulatory action date of January 2025. This leaves both parties with limited time to reach a settlement. Despite the reduction to our fair value estimate, we still believe Royalty Pharma’s shares are significantly undervalued given the diversity and quality of its portfolio.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Narrow-moat Royalty Pharma’s first-quarter results were in line with our expectations. We are leaving our $52 fair value estimate unchanged and continue to believe the market is undervaluing Royalty Pharma’s high-quality drug portfolio. With the recent addition of frexalimab (for relapsing multiple sclerosis), the company’s development-stage product pipeline looks increasingly attractive to us, which should support a high-single-digit annualized growth rate for its portfolio receipts over the next decade.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Narrow-moat Royalty Pharma reported fourth-quarter earnings slightly above our expectations. We maintain our fair value estimate of $52 per share after updating our drug sales forecasts. Our capital deployment projection of $2.6 billion annually between 2024 and 2028 remains intact, and we continue to think the market is underappreciating Royalty Pharma's diverse portfolio that is resilient to headwinds certain portfolio drugs might face. After the Feb. 15 3% rally, the stock is still trading in 5-star territory.

We have launched coverage of Royalty Pharma, the largest buyer of biopharmaceutical royalties with a portfolio of more than 35 commercial products and 10 development-stage product candidates. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high research and development or manufacturing costs. We assign Royalty Pharma a fair value estimate of $52 per share. The stock is currently trading in 5-star territory, roughly 45% below our fair value estimate. We believe Royalty Pharma has a narrow economic moat thanks to its high-quality royalty portfolio with an average royalty duration of around 12 years.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.